Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Inclusion Criteria: * Male or female, aged 0 to 3 years old (have not had their 4th birthday) on the day of consent. * Patients who are candidate for routine, uncomplicated cataract surgery in one eye with or without intraocular lens. * Patients whose caregiver(s) is/are able and willing to comply with all treatment and follow-up procedures. * Signed informed consent from (ICF) parents or patient's legally authorized representative(s). * Patients who have undergone routine, uncomplicated cataract surgery in one eye with or without intraocular lens. * Patients with clinical evidence of postoperative inflammation (anterior chamber inflammation grade \> 0). Exclusion Criteria: * Presence of any active or suspected viral, bacterial, or fungal disease in the study eye. * Active uveitis in the study eye. * Ocular neoplasia in the study eye. * Post-traumatic cataract in the study eye. * Suspected permanent low vision or blindness in the fellow non-study eye. The study eye must not be the patient's only good eye. * Use of any topical medication in the study eye within 2 days prior to surgery, except for those required for ocular examination or preoperative preparation. * Systemic administration of any steroidal anti inflammatory drugs in the previous 2 weeks prior to the surgery. * Systemic administration of any non-steroidal anti inflammatory drugs in the previous 48 hours prior to the surgery. * Patient or patient's breastfeeding mother who is expected to use corticosteroids (ex…